Evidence map›Paper›PMID 25869099›Full record

ArticleOncotarget2015

B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.

Fei Fei, Eun Ji Joo, Somayeh S Tarighat, Isabelle Schiffer, Helicia Paz, Muller Fabbri, Hisham Abdel-Azim, John Groffen, Nora Heisterkamp

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 95 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Fei FeiSection of Molecular Carcinogenesis, Division of Hematology/Oncology and Bone Marrow Transplant, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Eun Ji JooSection of Molecular Carcinogenesis, Division of Hematology/Oncology and Bone Marrow Transplant, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Somayeh S TarighatSection of Molecular Carcinogenesis, Division of Hematology/Oncology and Bone Marrow Transplant, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Isabelle SchifferSection of Molecular Carcinogenesis, Division of Hematology/Oncology and Bone Marrow Transplant, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Helicia PazSection of Molecular Carcinogenesis, Division of Hematology/Oncology and Bone Marrow Transplant, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Muller FabbriDepartment of Pediatrics, Molecular Microbiology and Immunology, Keck School of Medicine, Norris Comprehensive Cancer Center, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA.
Hisham Abdel-AzimDivision of Hematology/Oncology and Bone Marrow Transplant, Children's Hospital Los Angeles, Los Angeles, CA, USA.
John GroffenSection of Molecular Carcinogenesis, Division of Hematology/Oncology and Bone Marrow Transplant, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Nora HeisterkampSection of Molecular Carcinogenesis, Division of Hematology/Oncology and Bone Marrow Transplant, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Children's Hospital of Los Angeles · USUniversity of Southern California · USUSC Norris Comprehensive Cancer Center · US

Funding

TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIsR01CA090321 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI HEISTERKAMP, NORA C · 2001 to 2017
$4.4M
Microenvironment-Leukemia Communication Through LectinsR01CA172040 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI GROFFEN, JOHN H, HEISTERKAMP, NORA C · 2013 to 2017
$1.7M
NCI NIH HHS CA090321NCI NIH HHS CA172040NCI NIH HHS R01 CA090321NCI NIH HHS R01 CA172040
6 · The paper itself

Abstract

The molecular interactions between B-cell precursor acute lymphoblastic leukemia (pre-B ALL) cells and stromal cells in the bone marrow that provide microenvironmentally-mediated protection against therapeutic drugs are not well-defined. Galectin-3 (Lgals3) is a multifunctional galactose-binding lectin with reported location in the nucleus, cytoplasm and extracellular space in different cell types. We previously reported that ALL cells co-cultured with stroma contain high levels of Galectin-3. We here establish that, in contrast to more mature B-lineage cancers, Galectin-3 detected in and on the ALL cells originates from stromal cells, which express it on their surface, secrete it as soluble protein and also in exosomes. Soluble and stromal-bound Galectin-3 is internalized by ALL cells, transported to the nucleus and stimulates transcription of endogenous LGALS3 mRNA. When human and mouse ALL cells develop tolerance to different drugs while in contact with protective stromal cells, Galectin-3 protein levels are consistently increased. This correlates with induction of Galectin-3 transcription in the ALL cells. Thus Galectin-3 sourced from stroma becomes supplemented by endogenous Galectin-3 production in the pre-B ALL cells that are under continuous stress from drug treatment. Our data suggest that stromal Galectin-3 may protect ALL cells through auto-induction of Galectin-3 mRNA and tonic NFκB pathway activation. Since endogenously synthesized Galectin-3 protects pre-B ALL cells against drug treatment, we identify Galectin-3 as one possible target to counteract the protective effects of stroma.

Indexed as

Paracrine CommunicationSignal TransductionActive Transport, Cell NucleusAnimalsAntineoplastic AgentsBlood ProteinsCell Line, TumorEndocytosisExosomesGalectin 3GalectinsGene Expression Regulation, LeukemicHumansMice, Inbred C57BLMice, KnockoutNF-kappa BAntineoplastic AgentsBlood ProteinsGalectin 3GalectinsLGALS3 protein, humanLgals3 protein, mouseNF-kappa BRNA, Messengerdrug resistanceexosomesLgals3microenvironmentstroma

Identifiers

PMID25869099
PMCPMC4484463
OpenAlexW1507575667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.